Receptor Imaging

  • F. C. L. Wong
  • E. E. Kim
Chapter

Abstract

Although the idea of a receptor as a molecular entity has been around since the turn of the century, it remained elusive until 1976, when Snyder proved its existence [1]. Before that time, the best evidence of receptors and subtypes of receptors was derived from bioassays. These earlier studies were technically tedious and involved a wide range of variances. Since 1976, the understanding of receptors, subtypes of receptors and development of receptor methodologies has made great advances. The development of receptor technology in pharmacology, indeed, has benefited from earlier studies of antibody-antigen interactions, as pioneered by Yalow [2]. Despite differences in molecular weights of the entities involved, both antibody-antigen interactions and drug-receptor interactions are governed by the same mass-action laws that underlie all ligand-protein reactions.

Keywords

Receptor Imaging Medial Rectus Ceptor Density Tracer Ligand Receptor Imaging Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Snyder SM, Bennett JD (1976) Neurotransmitter receptors in the brain: biochemical identification. Ann Rev Physiol 38:153–175CrossRefGoogle Scholar
  2. 2.
    Yalow RS, Berson SA (1971) Introduction and general considerations. In: Odele WD, Daughaday WH (eds) Principles of competitive protein binding assays. Lippincott, Philadelphia, p 1Google Scholar
  3. 3.
    Wong FCL, Ho B, Lu IG, Fan SH, Myen R, Yang DJ, Kim EE (1993) Affinity labeling of neuroreceptors using gamma rays. J Nucl Med 34[suppl]:26Google Scholar
  4. 4.
    Wagner HN, Barns HD, Dannals RJ, Wong DF, Lang-strum B, Duelfer T, Frost JJ, Ravert HT, Links JM, Rosenbloom SB, Lukas SE, Kramer AV, Kuher MJ (1983) Imaging human dopamine receptors in the human brain. Science 221:1264–1266CrossRefPubMedGoogle Scholar
  5. 5.
    Wong DF, Wagner HN, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, Toung JKT, Malat J, Williams JA, O’Tauma LA, Snyder SH, Kuhar MJ, Gjedde A (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234:1558–1563CrossRefPubMedGoogle Scholar
  6. 6.
    Wong DF, Pearlson G, Tune LE, et al. (1987) In vivo measuresments of D2 dopamine receptor abnormalities in drug-naive and treated manic depressive patients. J Nucl Med 28:611Google Scholar
  7. 7.
    Kung HF, Slavi A, Chang W, King MP, Keyes JW Jr, Velchik MG, Billings J, Pan S, Noto R, et al. (1990) In vivo SPECT imaging of CNS D2 dopamine receeptors: initial studies with Iodine-123 IBZM in humans. J Nucl Med 31:573–578PubMedGoogle Scholar
  8. 8.
    Eckelman WC (1982) The testing of putative receptor binding radiotracers in vivo. In: Diksic M, Reba RC (eds) Radiopharmaceuticals and brain pathology studies with PET and SPECT. CRC Press, Boca Raton, pp 42–62Google Scholar
  9. 9.
    Vera DR, Krohn KA, Scheibe PO, Stadolnil RC (1985) Identifiability analysis of an in vivo receptor-binding radiopharmacokinetic system. IEEE Trans Biomed Eng 32:312–322PubMedCrossRefGoogle Scholar
  10. 10.
    Yung BCK, Wand GS, Blevins L, Dannals RF, Ravert HT, Chan B, Wong DF (1993) In vivo assessment of dopamine receptor density in pituitary macroadenoma and correlation with in vitro assay. J Nucl Med 34:133Google Scholar
  11. 11.
    Junck L, Olson JM, Ciliax BJ, Koeppe RA, Watkins GL, Jewett DM, McKeever PE, Wieland DM, Kilbourn MR, Starosta-Rubinstein S, et al. (1989) PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding sites. Ann Neurol 26:752–758CrossRefPubMedGoogle Scholar
  12. 12.
    Raderer M, Becherer A, Kurtaran A, Angelberger P, Li S, Leimer M, Weinlaender G, Kornek G, Kletter K, Scheithauer W, Virgolini I (1996) Comparison of Iodine-123-vasoactive intestinal peptide receptor scintigraphy and Indium-111 CFT-103 immunoscintigraphy. J Nucl Med 37:1480–1487PubMedGoogle Scholar
  13. 13.
    Starosta-Rubinstein S, Ciliax BJ, Penney JB, McKeever P, Young A (1980) Imaging of a glioma using peripheral benzodiazepine receptor ligands. Proc Natl Acad Sci USA 84:891–895CrossRefGoogle Scholar
  14. 14.
    Price GW, Ahier RG, Hume SP, Myers R, Manjil L, Cremer JE, Luthra SK, Pascali C, Pike V, Frackowiak RS (1990) In vivo binding to peripheral benzodiazepine binding sites in lesionai rat brain: comparison between [3H]-P/C11194 and [F18] PK 14105 as markers for neuronal damages. J Neurochem 55:175–185CrossRefPubMedGoogle Scholar
  15. 15.
    McGuire AH, Dehdashti F, Siegel BA, Lyss AP, Brodack JW, Mathias CJ, Mintun MA, Katzenellenbogen JA, Welch MJ (1991) Positron tomographic assessment of 16α-F18-fluoro 17-estradiol uptake in metastatic breast carcinoma. J Nucl Med 32:1526–1531PubMedGoogle Scholar
  16. 16.
    Reubi JC, Krenning E, Lamberts SW, Krols L (1990) Somatostatin receptors in malignant tissues. J Steroid Biochem Mol Biol 37:1073–1077CrossRefPubMedGoogle Scholar
  17. 17.
    Lambert SW, Bakker WH, Reubi JC, Krenning EP (1990) Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog. J Steroid Biochem Mol Biol 37:1079–1082CrossRefGoogle Scholar
  18. 18.
    Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooij PP, Reubi JC, Klijn JG, Visser TJ, Docter R, Lamberts SW (1990) Receptor scintigraphy with a radioio-dinated somatostatin analogue: radiolabeling, purification, biologic activity and in vivo application in animals. J Nucl Med 31:1501–1509PubMedGoogle Scholar
  19. 19.
    Faglia G, Bazzoni N, Spada A, Arosio M, Ambrosi B, Spinelli F, Sara R, Bonino C, Lunghi F (1991) In vivo detection of somatostatin receptors in patients with functionless pituitary xadenomas by means of a radio-iodinated analog of somatostatin I–123 SD2204-090. J Clin Endocrinol Metab 73:850–856CrossRefPubMedGoogle Scholar
  20. 20.
    Krenning EP, Kwekkeboom DJ, Panwels S, Kvols K, Reubi JC (1995) Somatostatin receptor scintigraphy. Ann Nucl Med 1:1–50Google Scholar
  21. 21.
    Buscail L, Delesque N, Estéve JP, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell GI, Liebow C, Schally AV, et al. (1994) Stimulation of toposine phosphatase and inhibition of cell proliferation by somatostatin analogues:mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 91:2315–2319PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Vallabhajosula S, Moyer BR, Lister-James J, McBride BJ, Lipszyc H, Lee H, Bastidas D, Dean RT (1996) Preclinical evaluation of technetium-99.-labeled somatostatin receptor-binding peptides. J Nucl Med 37:1016–1022PubMedGoogle Scholar
  23. 23.
    Smith-Jones PM, Stolz B, Borms C, et al. (1994) Ga-67/ Ga-68 [DFO] octreotide-A potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro as preliminary in vivo studies. J Nucl Med 35:317–325PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • F. C. L. Wong
  • E. E. Kim

There are no affiliations available

Personalised recommendations